American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 188-196 , August 2007

Diuretics Are Preferred Over Angiotensin II-Converting Enzyme Inhibitors For Initial Therapy of Uncomplicated Hypertension

    Pro
  • Richard Grimm, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Richard Grimm, MD, PhD, Hennepin County Medical Center, University of Minnesota, 701 Park Avenue, Minneapolis, MN 55415.

References 

  1. Novello RC, Sprague JM. Benzothiadiazine dioxides as novel diuretics. J Am Chem Soc. 1957;79:2028
  2. No authors listed Effects of treatment on morbidity in hypertension (Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg). JAMA. 1967;202:1028–1034
  3. Veterans Cooperative Group. Effects of treatment on morbidity in hypertension (II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg). JAMA. 1970;213:1143–1152
  4. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977;196:441–444
  5. Stafford RS, Monti V, Furberg CD, Ma J. Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension. 2006;48:213–218
  6. No authors listed Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program (II. Mortality by race-sex and age). JAMA. 1979;242:2572–2577
  7. Conway J, Lauwers P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation. 1960;21:21–27
  8. Zhu Z, Zhu S, Liu D, Cao T, Wang L, Tepel M. Thiazide-like diuretics attenuate agonist-induced vasoconstriction by calcium desensitization linked to Rho kinase. Hypertension. 2005;45:233–239
  9. No authors listed SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension (Final results of the Systolic Hypertension in the Elderly Program (SHEP)). JAMA. 1991;265:3255–3264
  10. Stamler J, Prineas RJ, Neaton JD, et al. Background and design of the new U.S. trial on diet and drug treatment of “mild” hypertension (TOMHS). Am J Cardiol. 1987;59:51G–60G
  11. ALLHAT Investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997
  12. Elmer PJ, Grimm R, Laing B, et al. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prev Med. 1995;24:378–388
  13. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study Research Group Treatment of Mild Hypertension Study (Final results). JAMA. 1993;270:713–724
  14. Neaton JD, Wentworth D Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease (Overall findings and differences by age for 316,099 white men). Arch Intern Med. 1992;152:56–64
  15. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967–1975
  16. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865–872
  17. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031
  18. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  19. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305–1315
  20. Smith WM. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res. 1977;40:I98–I105
  21. No authors listed Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program (I. Reduction in mortality of persons with high blood pressure, including mild hypertension). JAMA. 1979;242:2562–2571
  22. Grimm RH, Cohen JD, Smith WM, Falvo-Gerard L, Neaton JD. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT) (Six-year intervention results for men in special intervention and usual care groups). Arch Intern Med. 1985;145:1191–1199
  23. No authors listed Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial (Risk factor changes and mortality results). JAMA. 1982;248:1465–1477
  24. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592
  25. No authors listed Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616–1628
  26. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352–358
  27. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936–946
  28. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–2033
  29. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:1401–1409
  30. Wright JT, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:1636–1643
  31. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  32. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878
  33. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  34. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kid Dis. 2004;43(suppl 1):S1–S290
  35. Levey AS, Uhlig K. Editorial—Which antihypertensive agents in chronic kidney disease?. Ann Int Med. 2006;144:213–216
  36. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963–969
  37. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29–35
  38. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48:219–224
  39. Cutler JA. Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key?. Hypertension. 2006;48:198–200

PII: S0272-6386(07)00930-4

doi: 10.1053/j.ajkd.2007.06.007

American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 188-196 , August 2007

Article Tools

* Image Usage & Resolution